DMARDs for RA Improve Vascular Inflammation and CV Risk

DMARDs for RA Improve Vascular Inflammation and CV Risk

Use of a tumor necrosis factor inhibitor (TNFi) or triple therapy with conventional, synthetic disease-modifying antirheumatic drugs (DMARDs) for rheumatoid arthritis have similar beneficial effects in reducing patients’ vascular inflammation and cardiovascular risk, according to results from a randomized, active…

Read More